<DOC>
	<DOCNO>NCT00226811</DOCNO>
	<brief_summary>The study consist two part . In Part 1 study enrol 38 patient ( Step 1 Simon 2 step design ) Step 2 open total enrollment target study ( n=63 ) exceed due rapid enrollment ( 78 patient enter ) . Part 2 study open due final overall insufficiency efficacy observe 78 patient . Sunitinib ( SU011248 ) administer orally daily 4 week follow 2-week rest start dose 50 mg provision dose reduction base tolerability . All patient receive repeated cycle sunitinib disease progression , occurrence unacceptable toxicity , withdrawal criterion meet . After discontinuation treatment , patient follow order collect information antineoplastic therapy survival .</brief_summary>
	<brief_title>An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Gastric gastroesophageal junction adenocarcinoma cyto/histologically document Disease progression/ recurrence treatment one prior single agent combination chemotherapy regimen advance / metastatic disease ( last dose least 4 wks study entry ) . Patients may also receive prior adjuvant therapy recurrence occur &gt; 6 month adjuvant therapy completion Evidence measurable disease radiographic technique Adequate organ function . Clinically relevant ascites ( i.e . require paracentesis ) Severe weight loss NCI CTCAE Grade 3 hemorrhage &lt; 4 week start study treatment Diagnosis second malignancy within last 3 year History know brain metastasis , spinal cord compression , carcinomatous meningitis Known HIV Serious acute chronic illness Current treatment another clinical trial Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>